Intravenous aminophylline is used as a first line treatment for bronchial asthma. This preparation consists of theophylline or a salt of theophylline dissolved in a solution of ethylenediamine, which confers greater solubility and reduces the alkalinity of the drug.1 In clinical usage side effects of tachycardia, seizures and nausea are well known. We report on the much less common, but clinically important problem of allergy to the ethylenediamine component of aminophylline.
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CASE REPORT. A 57 -year-old lady was admitted with an infective exacerbation of chronic bronchitis and emphysema. Initial treatment was with nebulized bronchodilators, and intravenous aminophylline, hydrocortisone and ampicillin. Later on the day of admission the patient developed an erythematous macular rash, initially on the trunk and limbs, but becoming confluent with periorbital oedema. The rash was hot, itchy and uncomfortable, and the patient had paraethesia in her limbs. There was no clinical evidence of anaphylaxis and exfoliation did not occur. No history of drug allergy was given and medical notes were unavailable at this time. It was suspected the allergen was ampicillin, but discontinuation of this drug provided no relief. The patient remained on nebulized bronchodilators and an intravenous infusion of hydrocortisone and aminophylline. When the medical notes became available, close scrutiny revealed attendance at the ENT Clinic with otitis externa three years previously. At that time, treatment with Tri -Adcortyl cream (Squibb; triamcinolone acetate, gramicidin, neomycin, nystatin, ethylenediamine) was commenced, but later discontinued when a rash occurred around the ear. She was referred to the dermatology clinic where patch testing was performed. A strong positive reaction was found to ethylenediamine (1 %) which is a standard allergen in the European Standard Battery. She had not received aminophylline preparations in the past. The infusion of aminophylline was therefore discontinued and the rash subsided over the next few days. It is still possible that the allergen was ampicillin but a clear link to ethylenediamine is evident.
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The Ulster Medical Journal DISCUSSION Ethylenediamine is a substance used as a binding agent in a number of products, principally Tri -Adcortyl cream and aminophylline injection and enema. Reports of sensitization have been reported in hospital practice and industry.2,3 In addition, cross reaction has been observed with antihistamines4,5 and piperazine. 6 The allergic reaction can result in an exfoliative erythrodermic dermatitis which carries a significant morbidity and mortality. Neither the presence of ethylenediamine, nor the potential cross reaction are listed in the manufacturer's data sheet for Tri -Adcortyl cream, or for any of the commonly used aminophylline preparations. They are, however, mentioned in Martindale and the British Pharmacopoeia. This case illustrates the importance of careful examination of medical notes for such allergies, and clear warnings on the front cover of notes. It is also important to warn general practitioners, and indeed the patients themselves, of the potential risk. It is also worth remembering that in cases of drug allergy, the most obvious suspect is not always the correct one.
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